Leave a comment

European and Australian organisations sign international super cluster agreement

Six organisations representing life sciences and health clusters in Europe and Australia have signed a business development agreement today at BIO International Convention 2016 in San Francisco.

The agreement will help fast-track business results for companies and solve a common problem for small-to-medium enterprises (SMEs) – landing in new markets.

The organisations are from five regions: Adelaide (Australia), Catalonia (Spain), Auvergne-Rhone Alpes Region (France), Bavaria (Germany) and Piedmont (Italy).

The two Australian organisations, BioSA and Health Industries South Australia, signed the agreement on behalf of over 100 health industries companies and research organisations in Adelaide, a city with a fast-growing health and life sciences sector.

Fofo Australia agreement

“Everyone has been working very hard to deliver this agreement and I’m glad it has been finalised here at BIO 2016,” said Health Industries South Australia CE Marco Baccanti.

“This cooperative effort will deliver real, practical results for companies and research organisations across all our regions, and is particularly exciting for Adelaide as it focuses on growing its health industries.”

Over A$3 billion is being invested in health and life sciences infrastructure at Adelaide BioMed City – one of the largest health and life sciences clusters in the southern hemisphere, bringing together research, education, clinical care, and business incubation and development.

“This agreement will benefit South Australian companies targeting European markets enabling them to create networks for potential commercialisation partners and customers,” said Dr Meera Verma, Acting CE of BioSA.

“It will facilitate exports, research collaboration and commercial outcomes and provide opportunities for job creation within the high-tech health sector in South Australia.”

The four European clusters – Biocat (Catalonia, Spain), BioM (Bavaria, Germany), bioPmed (Piedmont, Italy) and Lyonbiopole (Auvergne-Rhone Alpes, France) – form bioXclusters PLUS alliance.

This super cluster comprises more than 3,300 SMEs, focusing on drug development, healthcare and medical technology.

This initiative is co-funded by the European Union’s COSME programme.

The EU’s Ambassador to Australia, Sem Fabrizi, said the COSME programme supports SME competitiveness by facilitating internationalisation and creating a single European entry point for global players, including from Australia, in the life sciences health sector.

“The EU is the world’s largest economy and has allocated more than A$3.5 billion over seven years for the COSME programme,” Ambassador Fabrizi said. “This agreement is another welcome development in the ever deepening economic ties between the EU and Australia.”

“Australia is an interesting business place for companies in Europe. In particular, this agreement will provide an easier direct access to academic and clinical research,” said BioM CEO Prof Dr Horst Domdey.

BioPmed Vice President Fabrizio Conicella is eyeing markets in Australia and beyond.

“Asia-Pacific is the fastest-growing healthcare market in the world, and it makes sense for European companies to target these markets from Australia,” said Mr Conicella.

The agreement will deliver opportunities across Europe and Australia, helping create connections between businesses, clinical research institutions and hospitals.

This will be achieved by:

  • Raising awareness about business opportunities in each other’s regions.
  • Providing government support to foster relationships between business, research, education and clinical care organisations.
  • Helping companies new to a region navigate local regulatory frameworks and make connections in the local business community.

One of the challenges life sciences research companies face is finding a way to commercialise their developments.

“Having strong connections to businesses in South Australia will be great for Catalan life sciences companies looking to commercialise their IP,” said Biocat CEO Dr Albert Barbera.

Lyonbiopole CEO Florence Agostino-Etchetto said ICT applied to healthcare is a fast growing sector.

“Australia has a strong focus on big data and AI research and companies in Lyon will be able to tap into this,” said Ms Agostino-Etchetto.


Media Contact:

Marco Baccanti, CE Health Industries South Australia
Mobile: +61 475 810 469
Email: marco.baccanti@sa.gov.au

1 Comment

Announcement of the mission to Japan (Oct. 9th – 14th, 2016)

The European Strategic Cluster Partnership alliance on Personalized Healthcare, bioXclusters+, gathering 4 European BioClusters – Biocat, BioM, BioPmed and Lyonbiopole – is glad to invite European SMEs based in the 4 bioXclusters+ regions to join the mission organized in the framework of BioJapan (Oct. 12 to 14, 2016).

This mission is organized in coordination with the EU-Japan Centre, that offers a “Biotech Cluster SME Mission” from Oct 10th to 14th 2016. Thus, European Clusters and SMEs, that are not partner of the bioXclusters+ alliance (see the details with bioXclusters+ regional contacts) and willing to join these missions are invited to apply through the EU-Japan Centre (deadline for submission: June 9th, 2016). Find all the details here: http://www.eu-japan.eu/events/biotech-cluster-sme-mission

The provisional mission program is:

  • Sunday Oct 9th : Arrival in Osaka – Japan
  • Monday Oct. 10th: Workshop about Japanese life science market and regulation in the morning – organized in collaboration with EU Japan Centre – and Cultural Visit in the afternoon.
  • Tuesday Oct. 11th: Participation in the 1-day “European Biotech & Pharma Partnering Conference” at Senri-Life Science Center in Osaka (organized in collaboration with Osaka Bio Headquarters and EU Japan Centre); transfer to Yokohama in the evening
  • From Oct. 12th to 14th: Participation at BioJapan 2016 (Yokohama).

Highlight on Tuesday Oct. 11th:  Free participation in the 1-day “European Biotech & Pharma Partnering Conference” at Senri-Life Science Center in Osaka with pre-arranged B-2-B meetings with companies from the Kansai regions – in cooperation with Osaka Bio Headquarters.

Through support of the European Commission and Osaka Bio Headquarters, participation in the Osaka conference is free of charge for European SMEs that will be part of the bioXclusters+ or the EU-Japan Centre delegation.

The European Biotech & Pharma Partnering Conference in Osaka event includes expert presentations in the morning on business opportunities for European companies in the Kansai region. In the afternoon, there will be pre-arranged 1-on-1 partnering meetings between the European and Japanese participants. Please find attached the provisional program and information about conference Hotels and Logistics.

Provisional program

Hotels and logistics

In order to ensure fruitful meetings, European cluster managers are asked to send short profiles of their participating companies in June, but the very latest before July 15th, 2016. Osaka Bio Headquarters then selects and invites relevant companies and business contacts in their region for each European participant. Please note that 1-on-1 partnering places are limited.

For more information regarding the mission and support provided for EU companies from bioXclusters+ regions, please contact your regional contact point:

Biocat: Jordi Fabrega (jfabrega@biocat.cat)

BioM: Dr. Stephanie Wehnelt (wehnelt@bio-m.org)

BioPmed: Alberto Baldi (baldi@bioindustrypark.it)

Lyonbiopole: Simon Gudin (simon.gudin@lyonbiopole.com)

For more information about EU Japan Centre mission:



Hosted by:

Hosting institutions

Leave a comment

The European Commission renews its support to the bioXclusters Alliance, “the European Strategic Cluster Partnership on Personalised Healthcare”

The European meta-cluster project bioXclusters+ (European Strategic Cluster Partnership on Personalised Healthcare) has been selected by the European Commission Executive Agency for Small and Medium-sized Entreprises (EASME) call for proposals COS-CLUSTER-2014-3-03 – Cluster Going International.

bioXclusters+  is a continuation of bioXclusters, first initiative funded by the EC from 2012 to 2014. The initiative gathers4 cluster partners: Biocat (Catalonia), BioM (Bavaria),  bioPmed/Bioindustry Park Silvano Fumero (Piemonte) and Lyonbiopole (Rhône-Alpes, project leader), aiming to reinforce and promote international competitiveness of their SMEs on strategic global markets. The new bioXclusters+ project, supported from 2016 to 2018, aims to address the next-decade European challenges related to healthcare and SMEs growth, thanks to a common vision of personalised healthcare as the paradigm for future global healthcare solutions. To address this new paradigm, the bioXclusters+ partnership intends to be the most competitive European meta-cluster initiative in personalised healthcare, delivering at global level cutting edge solutions through its innovation ecosystem and offering an entry point for global players to Europe.

In this regard, the consortium internationalisation strategy plan to focus their activities on three countries already explored (US, China and Brazil) but also on additional markets such as Japan.

The kick-off with representatives from the four clusters was held in January 26-27 in Lyon.


Outcomes from the initial 2-year pilot period of bioXclusters

The first 2-year action of bioXclusters was recognized as a real collective success, resulting in 11 agreements and collaborations between European SMEs and business partners of the US, China and Brazil markets. bioXclusters developed privileged links to the target regions with local science parks and cluster organisations, signing six Memorandums of Understanding offering key entry points for European SMEs to these markets. Moreover, bioXclusters partners built shared communication tools, as well as a Joint Action Strategy for internationalisation with a long term vision based on a trustful relationship. The project outcomes and recommendations for SMEs have been collected in a dedicated handbook available online.

Leave a comment

EU-Japan Cluster Matchmaking Event at BioEurope Report

The “EU‐Japan Cluster Matchmaking Event” was held at BIO‐Europe in Frankfurt, Germany, on November 3rd, 2014. Leading Japanese health care cluster representatives and their European counterparts met to build first bridges between their organisations in order to path the way for potential collaborations – and long-term to support SMEs to find business partners.

EU-Japan Foto Four key regions plus The Japan Bioindustry Association (JBA) outlined the vast array of opportunities that the Japanese pharma and health market offers to Europe. 30 attendees took also the advantage of exchanging business contacts and to meet people offering to help with building valuable connections in the otherwise difficult to approach Japanese market.

It is planned to follow up with a 2nd EU-Japan Cluster Matchmaking Event at BIO-Europe 2015 in Munich.

Report – EU-Japan matchmaking event

Leave a comment

EU-Japan Cluster Matchmaking Even at BioEurope – 3rd November 2014

The EU‐Japan Cluster Matchmaking Event – financially supported by the European Commission (http://www.clustercollaboration.eu) – is taking place at Bio Europe in Frankfurt (Germany) on November, 3rd. It provides the perfect opportunity to gain an overview of the strengths of the Japanese life sciences landscapes and clusters in the health care sector.

Speakers from four leading Japanese life science clusters and from Japan Bioindustry Association (JBA) will present the vast array of opportunities that the Japanese pharma and health market offers to European companies.

If you work for a European life science cluster or if you are a manager of a company that targets the Japanese market, do not miss the opportunity to establish valuable contacts at this event. It creates the basis for cluster cooperations, R&D projects, licensing opportunities, attracting joint partnerships, developing small scale, high value manufacturing projects, developing commercial activities and establishing your presence in the Japanese market by using soft landing facilities.

Agenda – EU-Japan matchmaking event

Your participation is free and no registration is required. For more information, please contact us:


USA Mission report

BioXclusters partners, along with some European SMEs, went to Boston (Massachusetts) last October 2013. Read the report we have produced with the description of the visits and information about the life sciences market.

The objective of the mission in Boston was to discover and detect key entry points of the biotech and medtech market in the USA and collaboration opportunities with the different organizations visited. The USA represents a key market in life sciences, and notably for Personalized Healthcare. With a life sciences sector weighting $61 billion and counting about 1.455 companies, among which 300 quoted in stock exchange, the USA is without any doubt the top-leading economy on this market.

The life sciences is indeed one of the most dynamic sector of the American economy were not less than $30 billion were invested for R&D in 2010. The American life sciences market alone accounts for 70% of the world turnover and for 15 % of the total sales of the biotechnologies market. Read more

1 Comment

Internationalisation in life sciences: the role of clusters

Internationalisation, especially in China, is considered sometimes as an issue by SMEs and clusters. In life science it is not an option. The activity of the sector cannot be constricted to national borders.

The market is global and the competition is global. SMEs are not always sure about how to face other markets that can offer big opportunities but also present big challenges.  In such scenario which is the role of clusters?

Internationalisation in Life Sciences – the whole text by Fabrizio Conicella


Get every new post delivered to your Inbox.

Join 28 other followers